BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 32223928)

  • 1. EGFR-independent EGFR-mutant lung adenocarcinoma cells depend on Bcl-xL and MCL1 for survival.
    Hirai S; Tada M; Yamaguchi M; Niki T; Sakuma Y
    Biochem Biophys Res Commun; 2020 May; 526(2):417-423. PubMed ID: 32223928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MCL1 inhibition enhances the therapeutic effect of MEK inhibitors in KRAS-mutant lung adenocarcinoma cells.
    Tada M; Sumi T; Tanaka Y; Hirai S; Yamaguchi M; Miyajima M; Niki T; Takahashi H; Watanabe A; Sakuma Y
    Lung Cancer; 2019 Jul; 133():88-95. PubMed ID: 31200834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual inhibition of KIF11 and BCL2L1 induces apoptosis in lung adenocarcinoma cells.
    Sakuma Y; Hirai S; Sumi T; Niki T; Yamaguchi M
    Biochem Biophys Res Commun; 2023 Oct; 678():84-89. PubMed ID: 37619315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in
    Nangia V; Siddiqui FM; Caenepeel S; Timonina D; Bilton SJ; Phan N; Gomez-Caraballo M; Archibald HL; Li C; Fraser C; Rigas D; Vajda K; Ferris LA; Lanuti M; Wright CD; Raskin KA; Cahill DP; Shin JH; Keyes C; Sequist LV; Piotrowska Z; Farago AF; Azzoli CG; Gainor JF; Sarosiek KA; Brown SP; Coxon A; Benes CH; Hughes PE; Hata AN
    Cancer Discov; 2018 Dec; 8(12):1598-1613. PubMed ID: 30254092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual inhibition of BCL2L1 and MCL1 is highly effective against RET fusion-positive or MET exon 14 skipping mutation-positive lung adenocarcinoma cells.
    Hirai S; Idogawa M; Sumi T; Yamaguchi M; Niki T; Sakuma Y
    Biochem Biophys Res Commun; 2022 Nov; 630():24-29. PubMed ID: 36126466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bcl-xL silencing induces alterations in hsa-miR-608 expression and subsequent cell death in A549 and SK-LU1 human lung adenocarcinoma cells.
    Othman N; In LL; Harikrishna JA; Hasima N
    PLoS One; 2013; 8(12):e81735. PubMed ID: 24339958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.
    Klanova M; Andera L; Brazina J; Svadlenka J; Benesova S; Soukup J; Prukova D; Vejmelkova D; Jaksa R; Helman K; Vockova P; Lateckova L; Molinsky J; Maswabi BC; Alam M; Kodet R; Pytlik R; Trneny M; Klener P
    Clin Cancer Res; 2016 Mar; 22(5):1138-49. PubMed ID: 26467384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.
    Yun M; Kim EO; Lee D; Kim JH; Kim J; Lee H; Lee J; Kim SH
    Cell Physiol Biochem; 2014; 34(3):865-72. PubMed ID: 25199820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X
    Yasuda Y; Ozasa H; Kim YH; Yamazoe M; Ajimizu H; Yamamoto Funazo T; Nomizo T; Tsuji T; Yoshida H; Sakamori Y; Nakajima N; Menju T; Yoshizawa A; Date H; Hirai T
    Cell Death Dis; 2020 Mar; 11(3):177. PubMed ID: 32152266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR mutations and AKT phosphorylation are markers for sensitivity to combined MCL-1 and BCL-2/xL inhibition in non-small cell lung cancer.
    Rice SJ; Liu X; Wang HG; Belani CP
    PLoS One; 2019; 14(5):e0217657. PubMed ID: 31150457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer.
    Stover EH; Baco MB; Cohen O; Li YY; Christie EL; Bagul M; Goodale A; Lee Y; Pantel S; Rees MG; Wei G; Presser AG; Gelbard MK; Zhang W; Zervantonakis IK; Bhola PD; Ryan J; Guerriero JL; Montero J; Liang FJ; Cherniack AD; Piccioni F; Matulonis UA; Bowtell DDL; Sarosiek KA; Letai A; Garraway LA; Johannessen CM; Meyerson M
    Mol Cancer Res; 2019 Nov; 17(11):2281-2293. PubMed ID: 31462500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BCL-XL regulates the timing of mitotic apoptosis independently of BCL2 and MCL1 compensation.
    Yu CY; Yeung TK; Fu WK; Poon RYC
    Cell Death Dis; 2024 Jan; 15(1):2. PubMed ID: 38172496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial-to-mesenchymal transition and its role in EGFR-mutant lung adenocarcinoma and idiopathic pulmonary fibrosis.
    Sakuma Y
    Pathol Int; 2017 Aug; 67(8):379-388. PubMed ID: 28678431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chaperone-mediated autophagy promotes lung cancer cell survival through selective stabilization of the pro-survival protein, MCL1.
    Suzuki J; Nakajima W; Suzuki H; Asano Y; Tanaka N
    Biochem Biophys Res Commun; 2017 Jan; 482(4):1334-1340. PubMed ID: 27939888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting melanoma's MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors.
    Sale MJ; Minihane E; Monks NR; Gilley R; Richards FM; Schifferli KP; Andersen CL; Davies EJ; Vicente MA; Ozono E; Markovets A; Dry JR; Drew L; Flemington V; Proia T; Jodrell DI; Smith PD; Cook SJ
    Nat Commun; 2019 Nov; 10(1):5167. PubMed ID: 31727888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibiting the expression of anti-apoptotic genes BCL2L1 and MCL1, and apoptosis induction in glioblastoma cells by microRNA-342.
    Ghaemi S; Arefian E; Rezazadeh Valojerdi R; Soleimani M; Moradimotlagh A; Jamshidi Adegani F
    Biomed Pharmacother; 2020 Jan; 121():109641. PubMed ID: 31751869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin-converting enzyme 2 is a potential therapeutic target for EGFR-mutant lung adenocarcinoma.
    Yamaguchi M; Hirai S; Sumi T; Tanaka Y; Tada M; Nishii Y; Hasegawa T; Uchida H; Yamada G; Watanabe A; Takahashi H; Sakuma Y
    Biochem Biophys Res Commun; 2017 Jun; 487(3):613-618. PubMed ID: 28433633
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MCL1 and BCL-xL levels in solid tumors are predictive of dinaciclib-induced apoptosis.
    Booher RN; Hatch H; Dolinski BM; Nguyen T; Harmonay L; Al-Assaad AS; Ayers M; Nebozhyn M; Loboda A; Hirsch HA; Zhang T; Shi B; Merkel CE; Angagaw MH; Wang Y; Long BJ; Lennon XQ; Miselis N; Pucci V; Monahan JW; Lee J; Kondic AG; Im EK; Mauro D; Blanchard R; Gilliland G; Fawell SE; Zawel L; Schuller AG; Strack P
    PLoS One; 2014; 9(10):e108371. PubMed ID: 25289887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYC directs transcription of MCL1 and eIF4E genes to control sensitivity of gastric cancer cells toward HDAC inhibitors.
    Labisso WL; Wirth M; Stojanovic N; Stauber RH; Schnieke A; Schmid RM; Krämer OH; Saur D; Schneider G
    Cell Cycle; 2012 Apr; 11(8):1593-602. PubMed ID: 22456335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NF-κB signaling is activated and confers resistance to apoptosis in three-dimensionally cultured EGFR-mutant lung adenocarcinoma cells.
    Sakuma Y; Yamazaki Y; Nakamura Y; Yoshihara M; Matsukuma S; Koizume S; Miyagi Y
    Biochem Biophys Res Commun; 2012 Jul; 423(4):667-71. PubMed ID: 22695117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.